Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Structural Heart and Valve Center, Division of Cardiology, Columbia University Medical Center, New York, New York; CRF-Skirball Center for Innovation, Orangeburg, New York, New York.
JACC Cardiovasc Interv. 2020 Oct 26;13(20):2427-2437. doi: 10.1016/j.jcin.2020.08.006.
The aim of this study was to evaluate the feasibility, procedural results, and 6-month outcomes of a novel transfemoral transcatheter mitral valve implantation (TMVI) system (Cephea) in patients with complex primary mitral regurgitation (MR).
TMVI is emerging as an alternative to surgery in patients with severe MR. To date, the great majority of TMVI systems use the transapical surgical approach.
This study included consecutive patients undergoing transfemoral TMVI with the Cephea valve system. All patients were suboptimal candidates for catheter-based repair for anatomic reasons. Patients underwent clinical, echocardiographic, and computed tomographic angiographic follow-up at 6 months. Main outcomes were procedural success, peri-procedural complications, and valve hemodynamic status early and at 6-month follow-up.
Three patients with severe primary MR (2 women, mean age 79 ± 3 years) at prohibitive surgical risk (mean European System for Cardiac Operative Risk Evaluation II score 13.8 ± 2.4%) were included. The valves were successfully implanted in all patients, with no procedural complications. Post-procedural echocardiography showed normal valve function in all patients (mean transvalvular gradient 3 mm Hg; range: 2 to 4 mm Hg), no moderate to severe valvular or paravalvular leak, and no clinically significant left ventricular outflow tract obstruction. At 6 months, all patients had improved quality of life (mean improvement vs. baseline 16.4 ± 12 points). All valve hemodynamic parameters were maintained. Computed tomographic angiography confirmed annular stability, proper valve geometry and no structural failure.
The transfemoral delivery of a purposely designed mitral prosthesis (Cephea valve) was safe and feasible in prohibitive risk patients. Valve performance was sustained, and clinical outcomes improved at 6 months. Larger clinical studies are required.
本研究旨在评估新型经股经导管二尖瓣置换术(TMVI)系统(Cephea)在复杂原发性二尖瓣反流(MR)患者中的可行性、程序结果和 6 个月的结果。
TMVI 作为严重 MR 患者的替代手术方法正在出现。迄今为止,绝大多数 TMVI 系统都使用经心尖手术入路。
本研究纳入了连续接受经股 TMVI 治疗的患者,采用 Cephea 瓣膜系统。所有患者均因解剖原因不适合经导管修复。患者在 6 个月时进行临床、超声心动图和计算机断层血管造影随访。主要结果是程序成功率、围手术期并发症以及瓣膜血流动力学状态的早期和 6 个月随访结果。
3 名严重原发性 MR(2 名女性,平均年龄 79 ± 3 岁)、手术风险极高(平均欧洲心脏手术风险评估系统 II 评分 13.8 ± 2.4%)的患者被纳入研究。所有患者均成功植入瓣膜,无手术并发症。术后超声心动图显示所有患者瓣膜功能正常(平均跨瓣梯度 3mmHg;范围:2 至 4mmHg),无中度至重度瓣叶或瓣周漏,无临床意义的左心室流出道梗阻。6 个月时,所有患者的生活质量均得到改善(与基线相比平均改善 16.4 ± 12 分)。所有瓣膜血流动力学参数均保持不变。计算机断层血管造影证实了瓣环的稳定性、瓣膜的适当几何形状和无结构失败。
在高风险患者中,经股递送专门设计的二尖瓣假体(Cephea 瓣膜)是安全可行的。瓣膜性能持续,6 个月时临床结果改善。需要更大的临床研究。